ChromaDex(CDXC) - 2025 Q1 - Quarterly Results

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES, CA - May 7, 2025 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was $4.9 m ...